Ryohei Katayama
Japanese Foundation For Cancer Research · 271 works · 14,004 citations · h-index 43
Top works
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
- Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
- Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.
- Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function
- Pim Kinases Promote Cell Cycle Progression by Phosphorylating and Down-regulating p27Kip1 at the Transcriptional and Posttranscriptional Levels
- Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer